Tailored Treatment: Pharmacogenomics Quiz

Pharmacogenomics is the study of how individual genetic variation affects drug metabolism, efficacy, and toxicity. Classical pharmacology historically assumed that a standard dose of a drug produces a predictable response across all patients. Pharmacogenomics recognizes that genetic differences in drug-metabolizing enzymes, transporters, and drug targets cause patients to respond differently to the same drug and dose. This knowledge enables clinicians to select the most appropriate drug and dosage for each individual, reducing adverse effects and improving therapeutic outcomes.

The cytochrome P450 enzyme family is responsible for metabolizing a large proportion of all clinically used drugs. Genetic polymorphisms in genes such as CYP2D6, CYP2C19, and CYP3A4 produce individuals who are poor metabolizers, intermediate metabolizers, extensive metabolizers, or ultra-rapid metabolizers of specific drugs. This metabolizer status directly affects plasma drug concentrations and clinical outcomes. Prescribing the standard dose to a poor metabolizer can cause drug accumulation and toxicity, while the same dose in an ultra-rapid metabolizer may produce insufficient therapeutic effect.

A poor metabolizer carries genetic variants, typically loss-of-function alleles, in drug-metabolizing enzyme genes that result in significantly reduced or absent enzyme activity. When these individuals receive standard doses of drugs metabolized by that enzyme, drug clearance is slower than normal, plasma concentrations rise higher and persist longer, and the risk of toxicity or adverse effects increases substantially. Recognizing poor metabolizer status through pre-prescription genotyping allows clinicians to reduce the dose or select an alternative drug to avoid harm.

Thiopurine methyltransferase, encoded by the TPMT gene, inactivates thiopurine drugs such as azathioprine and mercaptopurine. Patients with low-activity TPMT variants cannot efficiently inactivate these drugs, leading to accumulation of toxic active metabolites that cause severe myelosuppression and bone marrow failure. Genotyping or phenotyping TPMT activity before prescribing thiopurines is now standard clinical practice in many countries, allowing dose reduction in patients with intermediate TPMT activity and alternative drug selection for those with very low activity.

CYP2C19 genotyping identifies patients who metabolize clopidogrel poorly and may not convert it to its active antiplatelet form, guiding antiplatelet drug selection. HER2 testing determines eligibility for targeted trastuzumab therapy, and warfarin dosing is guided by CYP2C9 and VKORC1 genotypes that affect drug metabolism and target sensitivity. BRCA1 and BRCA2 genotyping is a cancer risk assessment tool rather than a pharmacogenomic application, as it predicts inherited cancer susceptibility rather than drug response or metabolism.

Warfarin, a widely used anticoagulant, has a narrow therapeutic window and highly variable dose requirements between patients. CYP2C9 variants affect the rate at which warfarin is metabolized and cleared, while VKORC1 variants affect the sensitivity of the drug's target enzyme, vitamin K epoxide reductase. Together, CYP2C9 and VKORC1 genotypes, along with clinical factors such as age and body weight, explain a large proportion of the inter-individual variation in warfarin dose requirements. Pharmacogenomics-guided warfarin dosing algorithms are recommended by clinical guidelines to reduce bleeding and thrombotic complications.

Precision oncology involves sequencing the genome of a patient's tumor to identify the specific somatic mutations, copy number changes, and gene fusions driving that individual cancer. This molecular profile guides selection of targeted therapies that are most likely to be effective against the specific drivers present in that tumor. Examples include EGFR-targeted therapies for non-small cell lung cancer with EGFR mutations, BRAF inhibitors for melanoma with BRAF V600E mutations, and BCR-ABL inhibitors for leukemia with the Philadelphia chromosome fusion.

An actionable genomic variant is one for which a specific, evidence-based clinical response exists. In the context of pharmacogenomics, an actionable variant might indicate that a patient should receive a dose adjustment or a different drug entirely. In oncology, an actionable somatic mutation might indicate eligibility for a specific targeted therapy. Clinical annotation databases such as PharmGKB, ClinVar, and the OncoKB repository curate and classify variants by the strength of evidence supporting clinical actionability.

Germline pharmacogenomic variants, such as CYP2D6, CYP2C19, and TPMT polymorphisms, are present in every cell of the body from conception and remain constant throughout a person's life. Unlike somatic tumor mutations, which can evolve over time, germline variants do not change and need only be determined once. Many healthcare institutions are developing pre-emptive pharmacogenomic testing programs that genotype patients for a panel of clinically relevant variants before they are ever prescribed the relevant drugs, placing results in the electronic health record for future prescribing decisions.

Tumor mutational burden measures how many somatic mutations are present in a tumor per megabase of genome sequenced. Tumors with high TMB produce many mutant peptide fragments, or neoantigens, that can be recognized by the immune system. High TMB has been shown to correlate with improved response to immune checkpoint inhibitor therapies that unleash the immune system against cancer cells. The FDA has approved pembrolizumab for TMB-high solid tumors regardless of tissue of origin, making TMB one of the first tumor-agnostic genomic biomarkers in clinical use.

Pharmacogenomic variation influencing drug response falls into three primary categories: metabolizing enzyme variants that alter drug clearance rates, transporter gene variants that affect cellular uptake and efflux of drugs, and drug target gene variants that change the affinity or activity of the molecular target. While mitochondrial DNA variation can influence drug-induced mitochondrial toxicity in some cases, it is not a standard primary category of pharmacogenomic variation and has far less clinical documentation than the three major categories involving enzymes, transporters, and targets.

Pharmacogenomic clinical decision support alerts are automated notifications embedded in electronic health record prescribing systems. When a clinician selects a drug for a patient whose genomic data indicates a relevant pharmacogenomic variant, an alert is triggered warning of predicted poor metabolism, potential toxicity, or reduced efficacy. These alerts provide actionable recommendations such as dose adjustment or alternative drug selection at the point of care. Institutions implementing pre-emptive pharmacogenomic testing programs use such alerts to translate genomic results into real-time clinical prescribing decisions.

Human leukocyte antigen genotyping is a pharmacogenomic application used to identify patients at high risk for severe immune-mediated adverse drug reactions. The HLA-B 5701 allele is strongly associated with abacavir hypersensitivity syndrome in HIV patients, and HLA-B 1502 is associated with Stevens-Johnson syndrome in patients of Southeast Asian ancestry taking carbamazepine. Prospective HLA genotyping before prescribing these drugs allows avoidance of life-threatening reactions in susceptible individuals. These are among the most compelling examples of pharmacogenomics preventing serious drug-related harm.

PharmGKB is a freely accessible pharmacogenomics knowledge base maintained by Stanford University that curates, integrates, and annotates the published literature on relationships between genetic variants and drug response. It provides evidence-graded pathway annotations, variant-drug-phenotype association summaries, and links to Clinical Pharmacogenomics Implementation Consortium guidelines. PharmGKB is a central resource for translating pharmacogenomics research findings into clinical guidelines and for researchers exploring gene-drug relationships across the growing pharmacogenomics literature.

Personalized medicine uses an individual's genomic profile alongside clinical data to optimize treatment selection, predict disease risk, and improve outcomes. Identifying genomic biomarkers predictive of drug response or disease progression is a central goal. Integrating genomic and clinical data provides the most complete picture for clinical decision-making. Personalized medicine does not replace all population-based guidelines; it refines and supplements them by applying genomic information where it adds meaningful predictive value to individual patient management.